AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer

ConclusionsOur findings encourage the continued evaluation of AR antagonists for BC treatment and support that AR pathway activity serves as a better prognostic factor than AR expression in BC.

http://link.springer.com/10.1007/s13402-019-00492-6

Source: Cellular Oncology - January 12, 2020 Category: Cancer & Oncology Source Type: research